Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Courteix

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Revue Medicale Suisse|August 31, 2007
[Antidepressants and pain]Alain Eschalier, Christine Courteix
Biomedicines|July 29, 2023
Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?Nazarine Mokhtar, Stephane Doly, Christine Courteix
Pain|December 1, 2000
Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic ratsMarie-Ange Coudoré-Civiale, Christine Courteix, Joseph Fialip, et al.
Expert Opinion on Drug Safety|May 5, 2020
The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trialsMarie Selvy, Mélissa Cuménal, Nicolas Kerckhove, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2007
Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonistChristine Courteix, Anne-Marie Privat, Teresa Pélissier, et al.
Pain|July 28, 2004
Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic painChristine Courteix, Marie-Ange Coudoré-Civiale, Anne-Marie Privat, et al.
Expert Opinion on Drug Safety|October 26, 2020
The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical TrialsMélissa Cuménal, Marie Selvy, Nicolas Kerckhove, et al.
Molecular Pharmacology|July 27, 2006
Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanismsLaurence Daulhac, Christophe Mallet, Christine Courteix, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 10, 2010
Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic painXavier Pichon, Anne S Wattiez, Carine Becamel, et al.
Neuropharmacology|August 7, 2017
Disruption of 5-HT<sub>2A</sub>-PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in ratsAnne-Sophie Wattiez, Amandine Dupuis, Anne-Marie Privat, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Revue Medicale Suisse|August 31, 2007
[Antidepressants and pain]Alain Eschalier, Christine Courteix
Biomedicines|July 29, 2023
Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?Nazarine Mokhtar, Stephane Doly, Christine Courteix
Pain|December 1, 2000
Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic ratsMarie-Ange Coudoré-Civiale, Christine Courteix, Joseph Fialip, et al.
Expert Opinion on Drug Safety|May 5, 2020
The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trialsMarie Selvy, Mélissa Cuménal, Nicolas Kerckhove, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2007
Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonistChristine Courteix, Anne-Marie Privat, Teresa Pélissier, et al.
Pain|July 28, 2004
Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic painChristine Courteix, Marie-Ange Coudoré-Civiale, Anne-Marie Privat, et al.
Expert Opinion on Drug Safety|October 26, 2020
The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical TrialsMélissa Cuménal, Marie Selvy, Nicolas Kerckhove, et al.
Molecular Pharmacology|July 27, 2006
Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanismsLaurence Daulhac, Christophe Mallet, Christine Courteix, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 10, 2010
Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic painXavier Pichon, Anne S Wattiez, Carine Becamel, et al.
Neuropharmacology|August 7, 2017
Disruption of 5-HT<sub>2A</sub>-PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in ratsAnne-Sophie Wattiez, Amandine Dupuis, Anne-Marie Privat, et al.
Pageof 2